Halozyme announces positive results from phase 3 trial
Halozyme Therapeutics announced the global phase III FeDeriCa study conducted by Genentech, a member of the Roche Group, met its primary endpoint. The study results demonstrated non-inferior levels of Perjeta® in the blood (pharmacokinetics) compared to standard IV infusion of Perjeta®. September 13, 2019